BidaskClub cut shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) from a hold rating to a sell rating in a research report sent to investors on Tuesday.

RARE has been the subject of a number of other research reports. Canaccord Genuity set a $80.00 price objective on shares of Ultragenyx Pharmaceutical and gave the company a buy rating in a research report on Tuesday, December 5th. Barclays boosted their price objective on shares of Ultragenyx Pharmaceutical from $60.00 to $62.00 and gave the company an equal weight rating in a research report on Tuesday, December 5th. Zacks Investment Research raised shares of Ultragenyx Pharmaceutical from a sell rating to a hold rating in a research report on Wednesday, November 8th. Raymond James Financial reissued a buy rating on shares of Ultragenyx Pharmaceutical in a research report on Friday, December 15th. Finally, JPMorgan Chase & Co. reissued a buy rating and issued a $76.00 price objective on shares of Ultragenyx Pharmaceutical in a research report on Sunday, November 5th. Two research analysts have rated the stock with a sell rating, eight have assigned a hold rating and ten have issued a buy rating to the company’s stock. The stock has a consensus rating of Hold and an average target price of $72.40.

Shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) traded down $1.99 on Tuesday, reaching $45.81. 362,000 shares of the company’s stock were exchanged, compared to its average volume of 404,910. The firm has a market capitalization of $2,035.76, a PE ratio of -6.57 and a beta of 1.83. Ultragenyx Pharmaceutical has a one year low of $43.14 and a one year high of $91.35.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.87) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($1.87). The business had revenue of $0.20 million for the quarter, compared to analyst estimates of $0.02 million. The business’s revenue was up 81.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.64) EPS. sell-side analysts forecast that Ultragenyx Pharmaceutical will post -7.31 EPS for the current year.

A number of institutional investors have recently added to or reduced their stakes in RARE. Capital Research Global Investors grew its stake in Ultragenyx Pharmaceutical by 1.4% during the second quarter. Capital Research Global Investors now owns 5,183,330 shares of the biopharmaceutical company’s stock worth $321,937,000 after buying an additional 71,811 shares during the period. BlackRock Inc. grew its stake in Ultragenyx Pharmaceutical by 10.4% during the second quarter. BlackRock Inc. now owns 3,497,591 shares of the biopharmaceutical company’s stock worth $217,237,000 after buying an additional 330,911 shares during the period. Vanguard Group Inc. grew its stake in Ultragenyx Pharmaceutical by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,130,273 shares of the biopharmaceutical company’s stock worth $194,421,000 after buying an additional 135,335 shares during the period. Capital International Investors grew its stake in Ultragenyx Pharmaceutical by 21.9% during the third quarter. Capital International Investors now owns 2,895,481 shares of the biopharmaceutical company’s stock worth $154,213,000 after buying an additional 520,496 shares during the period. Finally, State Street Corp boosted its stake in shares of Ultragenyx Pharmaceutical by 21.4% in the second quarter. State Street Corp now owns 1,536,285 shares of the biopharmaceutical company’s stock valued at $95,417,000 after purchasing an additional 270,729 shares during the period. Hedge funds and other institutional investors own 94.10% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.watchlistnews.com/ultragenyx-pharmaceutical-rare-rating-lowered-to-sell-at-bidaskclub/1810832.html.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies.

Analyst Recommendations for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.